| [1] Eskander RN, Tewari KS. Chemotherapy in the treatment of metastatic, persistent, and recurrent cervical cancer[J]. Curr Opin Obstet Gynecol, 2014,26(4):314-321.[2] Chao A, Lin CT, Lai CH. Updates in systemic treatment for metastatic cervical cancer[J]. Curr Treat Options Oncol,2014, 15(1):1-13.[3] Chao SH, Greenleaf AL, Price DH. Juglone, an inhibitor of the peptidyl-prolyl isomerase Pin1, also directly blocks transcription[J]. Nucleic Acids Res, 2001, 29(3):767-773.[4] Xu HL, Yu XF, Qu SC, et al. Anti-proliferative effect of Juglone from Juglans mandshurica Maxim on human leukemia cell HL-60 by inducing apoptosis through the mitochondria-dependent pathway[J]. Eur J Pharmacol, 2010, 645(1-3):14-22.[5] Wahedi HM, Lee TH, Moon EY,ey al.Juglone up-regulates sirt1 in skin cells under normal and UVB irradiated conditions[J]. J Dermatol Sci, 2016,81(3):210-212.[6] Fiorito S, Genovese S, Taddeo VA, et al.Novel juglone and plumbagin 5-O derivatives and their in vitro growth inhibitory activity against apoptosis-resistant cancer cells[J]. Bioorg Med Chem Lett,2016,26(2):334-337.[7] Fang F, Qin Y, Qi L,et al. Juglone exerts antitumor effect in ovarian cancer cells[J]. Iran J Basic Med Sci,2015, 18(6):544-548.[8] 张巍,吴亚猛,陈思瑶,等. 胡桃醌对宫颈癌SiHa细胞增殖及细胞周期的影响[J]. 吉林大学学报:医学版, 2015, 41(4):697-700.[9] Zhang W, Liu A, Li Y, et al. Anticancer activity and mechanism of juglone on human cervical carcinoma HeLa cells[J]. Can J Physiol Pharmacol, 2012,90(11):1553-1558.[10] 张巍,朱文赫,李妍,等.胡桃醌及其与顺铂联用对宫颈癌HeLa细胞存活和凋亡的影响[J]. 中国药理学与毒理学杂志,2013,27(4):663-666.[11] Hu YG, Shen YF, Li Y.Effect of Pin1 inhibitor juglone on proliferation, migration and angiogenic ability of breast cancer cell line MCF7Adr[J]. J Huazhong Univ Sci Technolog Med Sci, 2015,35(4):531-534.[12] 徐冶, 李质馨, 曹慧玲, 等. 3-甲基腺嘌呤对顺铂诱导HeLa细胞凋亡的影响[J].解剖学报, 2012, 43(1):59-62.[13] Logotheti S, Khoury N, Vlahopoulos SA, et al. N-bromotaurine surrogates for loss of antiproliferative response and enhances cisplatin efficacy in cancer cells with impaired glucocorticoid receptor[J]. Transl Res, 2016,S1931(16):101-108.[14] Nakano K, Sato Y, Toshiyasu T,et al. Predictive factors of head and neck squamous cell carcinoma patient tolerance to high-dose cisplatin in concurrent chemoradiotherapy[J]. Mol Clin Oncol, 2016,4(2):303-309.[15] Brown JR.The PI3K pathway:clinical inhibition in chronic lymphocytic leukemia[J]. Semin Oncol, 2016,43(2):260-264.[16] Tan ML, Ooi JP, Ismail N, et al. Programmed cell death pathways and current antitumor targets[J]. Pharm Res,2009, 26(7):1547-1560.[17] Bourdeanu L, Luu T.Targeted therapies in breast cancer:implications for advanced oncology practice[J]. J Adv Pract Oncol, 2014,5(4):246-260.[18] 刘倩,刘忠山,赵汝栋,等.顺铂增敏同步放化疗治疗中晚期宫颈癌的疗效[J].中国老年学杂志,2014,34(16):4712-4714..[19] 王蓓,邢邯英,李建立,等.阿司匹林对宫颈癌Hela细胞凋亡及增殖的影响[J].中国老年学杂志,2014,34(9):2459-2462. |
